Clinical Significance of Intracytoplasmic nm23-H1 Expression in Diffuse Large B-Cell Lymphoma

Clinical Cancer Research

Volumn 10, Issue 7, 2004, Pages 2482-2490

  Niitsu, Nozomi ^a   Nakamine, Hirokazu ^b   Okamoto, Masataka ^c   Akamatsu, Hiroko ^b   Higashihara, Masaaki ^a   Honma, Yoshio ^d   Okabe Kado, Junko ^d   Hirano, Masami ^c  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^c FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d SAITAMA CANCER CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 2 RECEPTOR; NUCLEOSIDE DIPHOSPHATE KINASE A;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOMA CELL; MAJOR CLINICAL STUDY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SERUM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; C-REACTIVE PROTEIN; CYTOPLASM; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODES; LYMPHOMA; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL, DIFFUSE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NUCLEOSIDE-DIPHOSPHATE KINASE; PROGNOSIS; TIME FACTORS;

EID: 1842479011     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0085     Document Type: Article

References (21)

1. Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med 1998 339:21-6.
2. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-42.
3. Shipp MA. A predictive model for aggressive non-Hodgkin's lymphomas. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987-94.
4. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature (Lond) 2000;403:503-11.
5. Niitsu N, Okabe-Kado J, Kasukabe T, Yamamoto-Yamaguchi Y, Umeda M, Honma Y. Prognostic implications of the differentiation inhibitory factor nm23-H1 protein in the plasma of aggressive non-Hodgkin's lymphoma. Blood 1999;94:3541-50.
6. Niitsu N, Okabe-Kado J, Nakayama M, et al. Plasma levels of the differentiation inhibitory factor nm23-H1 protein and their clinical implications in acute myelogenous leukemia. Blood 2000;96:1080-6.
7. Steeg PS, Bevilacqua G, Kopper L, et al. Evidence for a novel gene associated with low tumor metastatic potential. J Natl Cancer Inst (Bethesda) 1988;80:200-4.
8. Lascu I, Gonin P. The catalytic mechanism of nucleoside diphosphate kinases. J Bioenerg Biomembr 2000;32:237-46.
9. Niitsu N, Okabe-Kado J, Okamoto M, et al. Serum nm23-H1 protein as a prognostic factor in aggressive non-Hodgkin's lymphoma. Blood 2001;97:1202-10.
10. Okabe-Kado J. Serum nm23-H1 protein as a prognostic factor in hematological malignancies. Leuk Lymphoma 2002;43:859-67.
11. Niitsu N, Honma Y, Iijima K, et al. Clinical significance of nm23-H1 proteins expressed on cell surface in non-Hodgkin's lymphoma. Leukemia (Baltimore) 2003;17:196-202.
12. Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. WHO Health Organization Classification of Tumours. Pathology and Genetics. Tumours of Haematopoietic and Lymphoid Tissues, Lyon; IARC Press. 2001.
13. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971;31:1860-1.
14. Hirano M, Okamoto M, Maruyama F, et al. Alternating non-cross-resistant chemotherapy for non-Hodgkin's lymphoma of intermediate-grade and high-grade malignancy. A pilot study. Cancer (Phila) 1992; 69:772-7.
15. Niitsu N, Okamoto M, Kuraishi Y, Nakamura S, Kodama F, Hirano M. CyclOBEAP (cyclophosphamide, vincristine, bleomycin, etoposide, doxorubicin, prednisolone) regimen with granulocyte colony-stimulating factor (G-CSF) for patients with aggressive non-Hodgkin's lymphoma: a pilot study. The Adult Lymphoma Treatment Study Group. Eur J Haematol 2000;65:188-94.
16. Dursun A, Akyurek N, Gunel N, Yamac D. Prognostic implication of nm23-H1 expression in colorectal carcinomas. Pathology 2002;34: 427-32.
17. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
18. Wilcoxon F. Individual comparisons by ranking methods. Biometrics Bull 1945;1:80-3.
19. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50: 163-70.
20. Cox DR. Regression models and life tables. J Stat Soc Br 1972;34: 187-202.
21. Aryee DN, Simonitsch I, Mosberger I, et al. Variability of nm23-H1/ NDPK-A expression in human lymphomas and its relation to tumour aggressiveness. Br J Cancer 1996;74:1693-8.